Related Experiment Video
Updated: Aug 19, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
Management of thrombosis in cancer: primary prevention and secondary prophylaxis
1Department of Medicine, McMaster University, Hamilton, ON, Canada. alee@mcmaster.ca
Abstract:
Although traditional anticoagulant regimens are highly effective and safe in most patients with venous thromboembolism (VTE), the aggressive natural history of VTE and the high risk of serious bleeding in cancer patients can complicate the management of VTE. In addition, because few clinical trials have focused on the prevention and treatment of VTE in this unique patient population, many clinical questions regarding the care of cancer patients with VTE remain unanswered. Currently, low-molecular-weight heparins and oral vitamin K antagonists are the most commonly used agents for the primary and secondary prophylaxis of VTE in patients with or without cancer, but their use is associated with pharmacological and practical limitations. This review will provide an up-to-date summary of the clinical trials that have addressed the management of VTE in patients with cancer. A brief discussion of the potential application of novel anticoagulants in these clinical settings is also included.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Cancer Prevention
Some...
Cancer Prevention
Some...
Pulmonary Embolism III: Nursing Management
Levels of Health Promotion and Illness Prevention
In primary prevention, actions taken before disease onset prevent the disease from...